Skip to content

Released Nov 10, 2026, after the close

10-Q filed Nov 12, 2026, 43 days after period end · 0001628280-26-073392

Q3 2026 · 10-Q
Revenue$4.21M+243.9% vs Q3 2025no prior Q2 2026 on file
Net Income-$39.04MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.22N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$39,926,000N/M
Operating Cash Flowderived-$36,683,000N/M
Free Cash Flowderived-$36,981,000N/M
Margins · derived
Operating margin-947.7%+3458.3 pt vs Q3 2025
Net margin-926.7%+3202.4 pt vs Q3 2025

What the release said

On November 10, 2026, Prime Medicine, Inc. (the “Company”) announced that the preliminary unaudited estimates of its cash, cash equivalents, and short-term investments were approximately $61.2 million as of September 30, 2026, excluding its restricted cash of approximately $13.7 million.

Prime Medicine announced preliminary unaudited estimates of approximately $61.2 million in cash, cash equivalents, and short-term investments as of September 30, 2026, excluding restricted cash of approximately $13.7 million.1

The estimates are based on preliminary unaudited information, the quarter-end financial close is not yet complete, and PricewaterhouseCoopers LLP has not audited or reviewed them.12

Complete results as of September 30, 2026 will be included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.2

On November 10, 2026, the Company posted an updated corporate presentation to its website and attached it as Exhibit 99.1 to the Form 8-K.3

Preliminary unaudited cash, cash equivalents, and short-term investments
$61.2 million As of September 30, 2026, excluding restricted cash1
Restricted cash
$13.7 million Excluded from the $61.2 million figure; as of September 30, 20261
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$4.21M$1.23M$209.00K$0.00
Net Income-$39.04M-$50.58M-$52.52M-$50.71M
EPS Diluted-$0.22-$0.32-$0.44-$0.55

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR